P2Y receptors in the mammalian nervous system: pharmacology, ligands and therapeutic potential
- PMID: 22963441
- PMCID: PMC4354944
- DOI: 10.2174/187152712803581047
P2Y receptors in the mammalian nervous system: pharmacology, ligands and therapeutic potential
Abstract
P2Y receptors for extracellular nucleotides are coupled to activation of a variety of G proteins and stimulate diverse intracellular signaling pathways that regulate functions of cell types that comprise the central nervous system (CNS). There are 8 different subtypes of P2Y receptor expressed in cells of the CNS that are activated by a select group of nucleotide agonists. Here, the agonist selectivity of these 8 P2Y receptor subtypes is reviewed with an emphasis on synthetic agonists with high potency and resistance to degradation by extracellular nucleotidases that have potential applications as therapeutic agents. In addition, the recent identification of a wide variety of subtype-selective antagonists is discussed, since these compounds are critical for discerning cellular responses mediated by activation of individual P2Y receptor subtypes. The functional expression of P2Y receptor subtypes in cells that comprise the CNS is also reviewed and the role of each subtype in the regulation of physiological and pathophysiological responses is considered. Other topics include the role of P2Y receptors in the regulation of blood-brain barrier integrity and potential interactions between different P2Y receptor subtypes that likely impact tissue responses to extracellular nucleotides in the CNS. Overall, current research suggests that P2Y receptors in the CNS regulate repair mechanisms that are triggered by tissue damage, inflammation and disease and thus P2Y receptors represent promising _targets for the treatment of neurodegenerative diseases.
Similar articles
-
Pharmacology and structure of P2Y receptors.Neuropharmacology. 2016 May;104:50-61. doi: 10.1016/j.neuropharm.2015.10.030. Epub 2015 Oct 28. Neuropharmacology. 2016. PMID: 26519900 Review.
-
Tools and drugs for uracil nucleotide-activated P2Y receptors.Pharmacol Ther. 2018 Oct;190:24-80. doi: 10.1016/j.pharmthera.2018.04.002. Epub 2018 Apr 13. Pharmacol Ther. 2018. PMID: 29660366 Review.
-
P2X and P2Y nucleotide receptors as _targets in cardiovascular disease.Future Med Chem. 2013 Mar;5(4):431-49. doi: 10.4155/fmc.13.6. Future Med Chem. 2013. PMID: 23495690 Review.
-
ATP induces contraction of cultured brain capillary pericytes via activation of P2Y-type purinergic receptors.Am J Physiol Heart Circ Physiol. 2021 Feb 1;320(2):H699-H712. doi: 10.1152/ajpheart.00560.2020. Epub 2020 Dec 11. Am J Physiol Heart Circ Physiol. 2021. PMID: 33306443
-
Control of Macrophage Inflammation by P2Y Purinergic Receptors.Cells. 2021 May 4;10(5):1098. doi: 10.3390/cells10051098. Cells. 2021. PMID: 34064383 Free PMC article. Review.
Cited by
-
Altered purinergic receptor expression in the frontal cortex in schizophrenia.Schizophrenia (Heidelb). 2022 Nov 14;8(1):96. doi: 10.1038/s41537-022-00312-1. Schizophrenia (Heidelb). 2022. PMID: 36376358 Free PMC article.
-
State-dependent and -independent effects of dialyzing excitatory neuromodulator receptor antagonists into the ventral respiratory column.J Appl Physiol (1985). 2017 Feb 1;122(2):327-338. doi: 10.1152/japplphysiol.00619.2016. Epub 2016 Sep 29. J Appl Physiol (1985). 2017. PMID: 27687562 Free PMC article.
-
KV 7/M channels as _targets for lipopolysaccharide-induced inflammatory neuronal hyperexcitability.J Physiol. 2017 Feb 1;595(3):713-738. doi: 10.1113/JP272547. Epub 2016 Oct 2. J Physiol. 2017. PMID: 27506492 Free PMC article.
-
Neonatal Seizures and Purinergic Signalling.Int J Mol Sci. 2020 Oct 22;21(21):7832. doi: 10.3390/ijms21217832. Int J Mol Sci. 2020. PMID: 33105750 Free PMC article. Review.
-
Alterations of Purinergic Receptors Levels and Their Involvement in the Glial Cell Morphology in a Pre-Clinical Model of Autism Spectrum Disorders.Brain Sci. 2023 Jul 18;13(7):1088. doi: 10.3390/brainsci13071088. Brain Sci. 2023. PMID: 37509018 Free PMC article.
References
-
- Burnstock G, Knight GE. Cellular distribution and functions of P2 receptor subtypes in different systems. Int. Rev. Cytol. 2004;240:31–304. - PubMed
-
- Sak K, Webb TE. A retrospective of recombinant P2Y receptor subtypes and their pharmacology. Arch. Biochem. Biophys. 2002;397(1):131–136. - PubMed
-
- Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Knight GE, Fumagalli M, Gachet C, Jacobson KA, Weisman GA. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol. Rev. 2006;58(3):281–341. - PMC - PubMed
-
- Bodin P, Burnstock G. Purinergic signalling: ATP release. Neurochem. Res. 2001;26(8-9):959–969. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases